Europe
That would accelerate the company’s “decarbonization” plan by more than a decade.
Recipharm announces that it has this morning acquired 4,881,437 Consort Shares, representing 9.9 per cent. of the existing issued share capital of Consort Medical, at 1,010 pence per share and a further 118,563 Consort Shares, representing 0.2 per cent. of the existing issued share capital of Consort Medical at 1,000 pence per share.
Heidelberg Pharma AG announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany
The Withdrawal Agreement Bill passed in Britain’s House of Commons on Thursday, setting January 31st as the UK’s departure date from the EU, and potentially wrapping up one part of the three-year quagmire that is Brexit.
Companies from across the globe provide updates on their businesses and pipelines.
Tuesday afternoon the U.S. Food and Drug Administration approved Tepezza (teprotumumab-trbw) as the first treatment for this condition.
Exosomics SpA, the leading extracellular vesicles biotech company, announced that it has implemented NanoFCM Co., Ltd’s NanoAnalyzer instrument to offer sophisticated contract research and measurement services worldwide.
Voluntary public share buyback offer against cash payment in a purchase price range of EUR 1.60 to EUR 1.85 per share
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models
Sensyne Health plc, the British Clinical AI technology company, announces its Interim Results for the 6 months ended 31 October 2019.
PRESS RELEASES